Profile data is unavailable for this security.
About the company
BioVie Inc. is a clinical-stage company engaged in developing drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate NE3107 inhibits inflammatory activation of extracellular single-regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions. In liver disease, its orphan drug candidate BIV201 (continuous infusion terlipressin) is for the treatment of refractory ascites due to liver cirrhosis. BIV201 is administered as a liquid formulation. The Company is also engaged in developing NE3107, an extracellular single-regulated kinase (ERK) inhibitor that selectively reduces neuroinflammation and insulin resistance. NE3107 is an orally administered small molecule to inhibit inflammation-driven insulin resistance and pathological inflammatory cascades.
- Revenue in USD (TTM)0.00
- Net income in USD-43.27m
- Incorporated2013
- Employees18.00
- LocationBioVie Inc680 W NYE LANE, SUITE 201CARSON CITY 89703United StatesUSA
- Phone+1 (775) 888-3162
- Websitehttps://www.bioviepharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lumos Pharma Inc | 2.05m | -34.03m | 24.51m | 33.00 | -- | 0.8962 | -- | 11.95 | -4.19 | -4.19 | 0.2526 | 3.37 | 0.0363 | -- | 9.47 | 62,151.52 | -60.27 | -29.78 | -68.62 | -32.32 | -- | -- | -1,659.39 | -2,937.61 | -- | -- | 0.00 | -- | 34.67 | -30.31 | -9.57 | -- | -- | -- |
| Biomx Inc | 0.00 | -26.17m | 24.55m | 58.00 | -- | 6.64 | -- | -- | -0.5433 | -0.5433 | 0.00 | 0.067 | 0.00 | -- | -- | 0.00 | -74.18 | -- | -101.74 | -- | -- | -- | -- | -- | -- | -21.95 | 0.7841 | -- | -- | -- | 7.59 | -- | -- | -- |
| Bullfrog AI Holdings, Inc. | 65.00k | -5.36m | 24.65m | 4.00 | -- | 7.38 | -- | 379.24 | -0.9042 | -0.9042 | 0.0108 | 0.4253 | 0.0455 | -- | -- | 16,250.00 | -374.94 | -- | -- | -- | 92.00 | -- | -8,239.82 | -- | -- | -67.87 | 0.00 | -- | 550.00 | -- | -91.11 | -- | -- | -- |
| Lipocine Inc | -2.85m | -16.35m | 25.19m | 17.00 | -- | 1.23 | -- | -- | -3.11 | -3.11 | -0.5417 | 3.83 | -0.0942 | -- | -- | -167,695.30 | -54.02 | -39.32 | -58.16 | -45.87 | -- | -- | -- | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
| Iterum Therapeutics PLC | 0.00 | -38.37m | 26.12m | 14.00 | -- | -- | -- | -- | -2.96 | -2.96 | 0.00 | -0.4743 | 0.00 | -- | -- | 0.00 | -82.44 | -118.12 | -108.84 | -199.23 | -- | -- | -- | -890,554.10 | -- | -- | 1.51 | -- | -- | -- | 13.64 | -- | -32.09 | -- |
| Unity Biotechnology Inc | 0.00 | -39.86m | 26.19m | 19.00 | -- | 0.9221 | -- | -- | -2.75 | -2.75 | 0.00 | 1.69 | 0.00 | -- | -- | 0.00 | -41.95 | -47.21 | -49.03 | -53.51 | -- | -- | -- | -6,395.92 | -- | -- | 0.00 | -- | -100.00 | -- | 10.36 | -- | -61.28 | -- |
| Acasti Pharma Inc | 0.00 | -38.77m | 26.79m | 32.00 | -- | 0.4142 | -- | -- | -5.06 | -5.06 | 0.00 | 6.88 | 0.00 | -- | -- | -- | -40.18 | -45.71 | -41.30 | -50.84 | -- | -- | -- | -69,798.47 | -- | -14.38 | 0.00 | -- | -- | -- | -332.11 | -- | -45.53 | -- |
| BioVie Inc | 0.00 | -43.27m | 27.08m | 18.00 | -- | 2.62 | -- | -- | -1.19 | -1.19 | 0.00 | 0.188 | 0.00 | -- | -- | 0.00 | -125.99 | -456.35 | -184.48 | -1,810.88 | -- | -- | -- | -- | -- | -- | 0.5764 | -- | -- | -- | -92.67 | -- | -- | -- |
| Ayala Pharmaceuticals Inc | 13.00k | -48.07m | 27.42m | 20.00 | -- | -- | -- | 2,109.04 | -7.46 | -7.46 | 0.0022 | -2.06 | -- | -- | -- | 650.00 | -- | -- | -- | -- | 0.00 | -- | -369,784.60 | -- | -- | -2.31 | -- | -- | -- | -- | -- | -- | -- | -- |
| bioAffinity Technologies Inc | 2.53m | -7.94m | 28.21m | 75.00 | -- | 4.74 | -- | 11.14 | -0.9036 | -0.9036 | 0.2895 | 0.5168 | 0.2482 | 144.95 | 6.16 | 33,766.67 | -77.80 | -- | -93.28 | -- | 31.26 | -- | -313.41 | -- | 1.76 | -- | 0.1983 | -- | 52,660.42 | -- | 2.66 | -- | -- | -- |
| Aprea Therapeutics Inc | 583.24k | -14.29m | 28.51m | 7.00 | -- | 1.16 | -- | 48.88 | -4.00 | -4.00 | 0.1613 | 4.89 | 0.0221 | -- | -- | 83,320.00 | -54.11 | -68.66 | -63.19 | -77.19 | -- | -- | -2,449.55 | -42,112.84 | -- | -- | 0.00 | -- | -- | -- | 87.32 | -- | 90.61 | -- |
| RenovoRx Inc | 0.00 | -10.23m | 28.98m | 8.00 | -- | -- | -- | -- | -1.01 | -1.01 | 0.00 | -0.2805 | 0.00 | -- | -- | 0.00 | -234.38 | -- | -317.07 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -3.47 | -- | -- | -- |
| Spruce Biosciences Inc | 10.09m | -47.92m | 29.52m | 29.00 | -- | 0.3847 | -- | 2.93 | -1.26 | -1.26 | 0.2622 | 1.86 | 0.1064 | -- | -- | 347,896.60 | -50.55 | -41.24 | -62.77 | -46.49 | -- | -- | -474.96 | -1,774.39 | -- | -107.65 | 0.0418 | -- | -- | -- | -3.77 | -- | -- | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -17.19m | 29.69m | 29.00 | -- | -- | -- | -- | -0.4079 | -0.4079 | 0.00 | -0.0803 | 0.00 | -- | -- | 0.00 | -271.62 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
Data as of May 02 2024. Currency figures normalised to BioVie Inc's reporting currency: US Dollar USD
2.68%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 326.38k | 0.54% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 319.84k | 0.53% |
| swisspartners Marcuard Heritage AGas of 30 Jun 2023 | 300.00k | 0.49% |
| Geode Capital Management LLCas of 31 Dec 2023 | 187.59k | 0.31% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 175.74k | 0.29% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 95.54k | 0.16% |
| Teachers Advisors LLCas of 31 Dec 2023 | 80.71k | 0.13% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 70.71k | 0.12% |
| Cerity Partners LLCas of 31 Dec 2023 | 40.74k | 0.07% |
| Millennium Management LLCas of 31 Dec 2023 | 36.96k | 0.06% |
More ▼
Data from 30 Jun 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
